Pathology: metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA); metastatic/advanced RCC (mRCC) - 1st line (L1);
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) | metastatic/advanced RCC (mRCC) - 1st line (L1) | |||
KEYNOTE-564, 0 | KEYNOTE-426, 2019 | KEYNOTE-581/CLEAR (PDL1), 2021 | ||
pembrolizumab alone | 1 | T1 | ||
pembrolizumab plus lenvatinib | 1 | T1 | ||
pembrolizumab plus axitinib | 1 | T1 | ||
placebo | 0 | T0 | ||
sunitinib | 0 | T0 | T0 |